Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Leuprolide Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 430,620Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Foresee Pharma: Casppian Ph 3 Study Meets LH Suppression Endpoint
    Foresee Pharma: Casppian Ph 3 Study Meets LH Suppression Endpoint

    24 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/foresee-pharmaceuticals-announces-the-casppian-phase-3-study-meets-primary-efficacy-endpoint-demonstrating-robust-lh-suppression-with-6-month-dosing-interval-of-leuprolide-mesylate-302649248.html

    PR NEWSWIRE
    24 Dec 2025
    Share Share
    Foresee Pharmaceuticals Announces FDA Approval of Camcevi ETM
    Foresee Pharmaceuticals Announces FDA Approval of Camcevi ETM

    29 Aug 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/foresee-pharmaceuticals-announces-fda-approval-of-camcevi-etm/

    CONTRACTPHARMA
    29 Aug 2025
    Share Share
    Foresee Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI
    Foresee Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI

    29 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/foresee-pharmaceuticals-announces-fda-orange-book-listing-of-new-us-patent-for-camcevi-extending-patent-protection-to-2039-301912712.html

    PR NEWSWIRE
    29 Aug 2023
    Share Share
    Foresee Announces Submission of NDA for FDA Approval of LMIS 50 mg
    Foresee Announces Submission of NDA for FDA Approval of LMIS 50 mg

    27 Jul 2020

    // PRNASIA

    https://en.prnasia.com/releases/global/foresee-pharmaceuticals-announces-submission-of-nda-for-fda-approval-of-lmis-50-mg-286512.shtml

    PRNASIA
    27 Jul 2020
    Share Share
    Foresee Pharma announces topline results of FP-001 LMIS in prostate cancer
    Foresee Pharma announces topline results of FP-001 LMIS in prostate cancer

    22 Feb 2019

    // BIOSPECTRUM

    https://www.biospectrumasia.com/news/39/12875/foresee-pharma-announces-topline-results-of-fp-001-lmis-in-prostate-cancer.html

    BIOSPECTRUM
    22 Feb 2019
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.